<DOC>
	<DOC>NCT01933958</DOC>
	<brief_summary>The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice</brief_summary>
	<brief_title>Regorafenib Post-marketing Surveillance in Japan</brief_title>
	<detailed_description>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. A total of 135 patients are to be enrolled and assessed in 6 months standard observational period. At 12 months and 24 months after the first administration of Regorafenib for confirmation of efficacy information including treatment duration and survival status of the patient.</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Patients who are treated with Regorafenib/ STIVARGA and meet the product label. Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Gastrointestinal stromal tumors</keyword>
</DOC>